DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-193563 | Chemical and Material
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Direct-To-Consumer Disease Risk And Health Genetic Test Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET
7.1 GLOBAL DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER DISEASE RISK AND HEALTH GENETIC TEST MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 23andMe
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 MyHeritage
16.3 LabCorp
16.4 Myriad Genetics
16.5 Ancestrycom
16.6 Quest Diagnostics
16.7 Gene By Gene
16.8 DNA Diagnostics Center
16.9 Invitae
16.10 IntelliGenetics
16.11 Ambry Genetics
16.12 Living DNA
16.13 EasyDNA
16.14 Pathway Genomics
16.15 Centrillion Technology
16.16 Xcode
16.17 Color Genomics
16.18 Anglia DNA Services
16.19 African Ancestry
16.20 Canadian DNA Services
16.21 DNA Family Check
16.22 Alpha Biolaboratories
16.23 Test Me DNA
16.24 23 Mofang
16.25 Genetic Health
16.26 DNA Services of America
16.27 Shuwen Health Sciences
16.28 Mapmygenome
16.29 Full Genomes
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeCeliac Disease
Parkinson Disease
Alzheimer Disease
Other
By Application
Online
Offline
Companies
23andMe
MyHeritage
LabCorp
Myriad Genetics
Ancestrycom
Quest Diagnostics
Gene By Gene
DNA Diagnostics Center
Invitae
IntelliGenetics
Ambry Genetics
Living DNA
EasyDNA
Pathway Genomics
Centrillion Technology
Xcode
Color Genomics
Anglia DNA Services
African Ancestry
Canadian DNA Services
DNA Family Check
Alpha Biolaboratories
Test Me DNA
23 Mofang
Genetic Health
DNA Services of America
Shuwen Health Sciences
Mapmygenome
Full Genomes
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.